Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Leases (2019 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Leases for 7 consecutive years, with $636000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases fell 10.8% to $636000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $636000.0 through Dec 2025, down 10.8% year-over-year, with the annual reading at $636000.0 for FY2025, 10.8% down from the prior year.
  • Current Leases for Q4 2025 was $636000.0 at Gyre Therapeutics, up from $626000.0 in the prior quarter.
  • The five-year high for Current Leases was $2.0 million in Q4 2021, with the low at $100000.0 in Q1 2024.
  • Average Current Leases over 5 years is $916176.5, with a median of $678000.0 recorded in 2021.
  • The sharpest move saw Current Leases plummeted 79.34% in 2022, then surged 705.0% in 2025.
  • Over 5 years, Current Leases stood at $2.0 million in 2021, then plummeted by 75.11% to $492000.0 in 2022, then tumbled by 57.32% to $210000.0 in 2023, then skyrocketed by 239.52% to $713000.0 in 2024, then fell by 10.8% to $636000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $636000.0, $626000.0, and $622000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.